The US FDA granted accelerated approval for Bristol-Myers Squibb's programmed cell death-1 (PD-1) inhibitor Opdivo (nivolumab) for the treatment of advanced melanoma more than three months earlier than expected.
The FDA accepted the Bristol-Myers biologic license application (BLA) for Opdivo and granted a breakthrough therapy designation for the immunotherapy...